One Capital Management LLC boosted its holdings in Pfizer Inc. (NYSE:PFE) by 1.9% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 83,333 shares of the biopharmaceutical company’s stock after purchasing an additional 1,534 shares during the period. One Capital Management LLC’s holdings in Pfizer were worth $2,994,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also modified their holdings of the company. Heritage Way Advisors LLC raised its position in shares of Pfizer by 0.6% during the 2nd quarter. Heritage Way Advisors LLC now owns 57,524 shares of the biopharmaceutical company’s stock worth $2,492,000 after purchasing an additional 354 shares during the period. Natixis bought a new position in Pfizer in the 2nd quarter worth approximately $258,466,000. Machina Capital S.A.S. grew its holdings in Pfizer by 14.4% in the 2nd quarter. Machina Capital S.A.S. now owns 43,837 shares of the biopharmaceutical company’s stock worth $1,899,000 after buying an additional 5,522 shares in the last quarter. Integrated Wealth Concepts LLC grew its holdings in Pfizer by 14.2% in the 2nd quarter. Integrated Wealth Concepts LLC now owns 68,060 shares of the biopharmaceutical company’s stock worth $2,840,000 after buying an additional 8,445 shares in the last quarter. Finally, Annex Advisory Services LLC grew its holdings in Pfizer by 0.7% in the 2nd quarter. Annex Advisory Services LLC now owns 51,785 shares of the biopharmaceutical company’s stock worth $2,243,000 after buying an additional 382 shares in the last quarter. 71.66% of the stock is owned by hedge funds and other institutional investors.
Shares of PFE traded up $0.22 during mid-day trading on Tuesday, reaching $36.68. The company’s stock had a trading volume of 325,831 shares, compared to its average volume of 16,028,038. The business has a fifty day moving average of $36.25 and a 200 day moving average of $39.64. The company has a market cap of $202.08 billion, a price-to-earnings ratio of 12.23, a price-to-earnings-growth ratio of 2.16 and a beta of 0.66. Pfizer Inc. has a 1 year low of $33.97 and a 1 year high of $46.47. The company has a quick ratio of 1.21, a current ratio of 1.47 and a debt-to-equity ratio of 0.60.
Pfizer (NYSE:PFE) last released its earnings results on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.75 by $0.05. The company had revenue of $13.26 billion during the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 28.10% and a net margin of 23.58%. The company’s revenue for the quarter was down 1.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.77 earnings per share. On average, analysts predict that Pfizer Inc. will post 2.82 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be issued a $0.36 dividend. The ex-dividend date is Thursday, November 7th. This represents a $1.44 dividend on an annualized basis and a dividend yield of 3.93%. Pfizer’s payout ratio is currently 48.00%.
In other news, Director Scott Gottlieb acquired 3,000 shares of the business’s stock in a transaction that occurred on Friday, August 23rd. The stock was acquired at an average cost of $34.72 per share, for a total transaction of $104,160.00. Following the completion of the acquisition, the director now owns 3,000 shares in the company, valued at $104,160. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Pfizer Inc acquired 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 17th. The shares were purchased at an average price of $18.00 per share, with a total value of $900,000.00. The disclosure for this purchase can be found here. 0.09% of the stock is owned by corporate insiders.
A number of equities analysts recently issued reports on PFE shares. DZ Bank raised Pfizer from a “sell” rating to a “hold” rating and set a $36.00 price objective for the company in a report on Wednesday, August 28th. ValuEngine raised Pfizer from a “sell” rating to a “hold” rating in a report on Wednesday, October 2nd. Morgan Stanley decreased their price objective on Pfizer from $40.00 to $38.00 and set an “equal weight” rating for the company in a report on Tuesday, August 27th. JPMorgan Chase & Co. increased their price objective on Pfizer from $37.00 to $46.00 and gave the stock a “neutral” rating in a report on Thursday, September 19th. They noted that the move was a valuation call. Finally, UBS Group reaffirmed a “neutral” rating and set a $43.00 price target on shares of Pfizer in a research note on Monday, August 5th. Twelve analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $44.47.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Further Reading: How does a security become overbought?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.